Absci Corporation (ABSI)
NASDAQ: ABSIHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 9.22 0.00%
ABSI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.58B
- EPS (TTM)
- -$0.79
- Dividend yield
- None
- 52-week range
- 2.24 – 12.06
- Day range
- 9.13 – 10.22
- Volume / Avg
- 5.82M / 3.46M
- Beta
- —
- Shares outstanding
- 171.61M
52-week range
ABSI stock today
Absci (ABSI) closed at $9.22 on Oct 7, down 10.22% (-$1.05), versus the S&P 500's 0.22% decline. Shares are 23.5% below their 52-week high of $12.06 and 311.6% above the 52-week low of $2.24, in the middle of the past year's range. Absci has posted a net loss over the last twelve months (EPS of -$0.79), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Absci
Company profileAbsci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Sean McClain
- Headquarters
- Vancouver, WA
- Employees
- 140
- IPO year
- 2021
- Website
- absci.com
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$14.40+56.18%
- Strong buy 2
- Buy 8
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Absci peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GENBGenerate Biomedicines Inc. | 13.57 | -1.67% | $1.74B | vs ABSI |
| BHVNBiohaven Ltd. | 11.88 | -1.66% | $1.79B | vs ABSI |
| XNCRXencor Inc. | 24.26 | -0.41% | $1.80B | vs ABSI |
| MESOMesoblast Limited ADR | 13.94 | +2.42% | $1.81B | vs ABSI |
| NUVBNuvation Bio Inc. Class A | 4.86 | -0.41% | $1.71B | vs ABSI |
| ZBIOZenas BioPharma Inc. | 28.18 | +4.60% | $1.84B | vs ABSI |
| SEPNSepterna Inc. | 36.00 | +0.93% | $1.68B | vs ABSI |
| SRPTSarepta Therapeutics Inc. | 17.50 | +1.10% | $1.85B | vs ABSI |
Indexes, lists and sector
Appears in lists
Absci stock FAQ
What is Absci's stock price today?
ABSI last traded at $9.22 as of Oct 7, 4:00 PM EDT, down 10.22% on the day. Prices are delayed at least 15 minutes.
Who is Absci's CEO?
Mr. Sean McClain is the chief executive officer of Absci Corporation, which has about 140 employees.
What is the ABSI 52-week high?
The 52-week high for ABSI is $12.06 and the 52-week low is $2.24. The stock is currently 23.5% below its high.